A combined treatment of systemic FMS-like tyrosine kinase 3 ligand (FLT3L) and poly I:C at the tumor sites, which induced the expansion and maturation of CD103+ cDC1s, improved the efficacy of BRAF and PD-L1 blockade, suggesting that combined FLT3L and poly I:C therapy might be a promising approach that could improve the efficacy of current ICB immunotherapy in cancer patients (93). This evidence concerns the gene CD274 and neoplasm.